Opus Genetics Inc
NASDAQ:IRD

Watchlist Manager
Opus Genetics Inc Logo
Opus Genetics Inc
NASDAQ:IRD
Watchlist
Price: 2.55 USD 8.05% Market Closed
Market Cap: 175.8m USD

Operating Margin

-235.6%
Current
Declining
by 124.9%
vs 3-y average of -110.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-235.6%
=
Operating Income
$-34.5m
/
Revenue
$14.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-235.6%
=
Operating Income
$-34.5m
/
Revenue
$14.6m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Opus Genetics Inc
NASDAQ:IRD
152.3m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.5B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.1B USD
Loading...

Market Distribution

Lower than 89% of companies in the United States of America
Percentile
11th
Based on 14 112 companies
11th percentile
-235.6%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Opus Genetics Inc
Glance View

Market Cap
175.8m USD
Industry
Pharmaceuticals

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

IRD Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-235.6%
=
Operating Income
$-34.5m
/
Revenue
$14.6m
What is Opus Genetics Inc's current Operating Margin?

The current Operating Margin for Opus Genetics Inc is -235.6%, which is below its 3-year median of -110.7%.

How has Operating Margin changed over time?

Over the last 3 years, Opus Genetics Inc’s Operating Margin has decreased from 45.7% to -235.6%. During this period, it reached a low of -329% on Sep 30, 2024 and a high of 50.8% on Sep 30, 2023.

Back to Top